Focused Ultrasound Foundation Establishes Pioneering Research Initiative in London Under International Center of Excellence

 Focused Ultrasound Foundation Establishes Pioneering Research Initiative in
           London Under International Center of Excellence Program

  PR Newswire

  LONDON, September 5, 2013

LONDON, September 5, 2013 /PRNewswire/ --

Focused Ultrasound Foundation, Royal Philips, The Institute of Cancer
Research, and The Royal Marsden collaborate in center to accelerate progress
and establish global standards for focused ultrasound treatment   ̶ 
enhancing patient care around the world

 (Photo: http://photos.prnewswire.com/prnh/20130905/638204 )

The Focused Ultrasound Foundation and Royal Philips (NYSE: PHG, AEX: PHIA)
have entered into an innovative public-private collaboration with The
Institute of Cancer Research , London, and The Royal Marsden NHS Foundation
Trust. The partnership will create a focal point for ultrasound therapy
research at The Institute of Cancer Research (ICR) and The Royal Marsden in
London under the international Focused Ultrasound Foundation Centers of
Excellence Program.

The new initiative will create a state-of-the-art resource for clinicians and
scientists working on high intensity focused ultrasound therapy, developing
clinical evidence in oncology and establishing best practices, treatment
standards and protocols. Focused ultrasound concentrates ultrasound energy
with high precision on target tissue in the body to thermally destroy tissue.
The technology is coupled with image guidance to identify, target and track
the treatment in real time. The initiative will launch this autumn with a
clinical trial to evaluate treatment of bone metastases in cancer patients. A
similar center was established at the University of Virginia in 2009 to
advance the use of focused ultrasound, with an emphasis on brain disorders.

"High intensity focused ultrasound therapy has tremendous potential in
oncology and many other key clinical areas," noted Gail ter Haar, DSc.,
coordinator of the initiative. "To achieve this, we need to collaborate in new
ways, establish standards for consistent delivery of treatment and train those
who will deliver that care. All of that will be happening here, thanks to the
Focused Ultrasound Foundation. We are excited and honored to be a part of the
network whose aim is to improve treatment outcomes for patients around the
world." 

The Focused Ultrasound Foundation is the catalyst for the collaboration and
its leadership will actively engage with the ICR, The Royal Marsden and
Philips to help guide progress towards standard-setting translational and
clinical research, training and treatment. In establishing the Focused
Ultrasound Centers of Excellence Program, the Foundation brings together the
best people and resources at luminary research sites throughout the world in
the dynamic multi-disciplinary environment necessary to foster those
activities critical to accelerating progress towards better patient outcomes.

"The new initiative established at the ICR and The Royal Marsden under the
Focused Ultrasound Foundation Centers of Excellence Program is an important
step forward for the technology," noted Neal F. Kassell, M.D., founder and
chairman of the Focused Ultrasound Foundation. "Our Centers of Excellence not
only demonstrate exceptional technical and clinical expertise in the field of
focused ultrasound, but also contribute to a synergistic network, leveraging
expertise and sharing best practices."

"Our contribution to the center will help to bring focused ultrasound
technology to a higher level of maturity and shape the standard of care for
patients around the world," said Falko Busse, General Manager MR-Therapy at
Philips Healthcare. "The ICR and The Royal Marsden are a perfect choice, being
established global leaders in cancer research with an impressive track record
of bringing new technologies and approaches to cancer care along with rigorous
evidence-based standards. Prof. Ter Haar and her group are pioneers in focused
ultrasound therapy and are particularly strong in the standardization
necessary for widespread adoption."

The center will be led by Prof. Gail ter Haar and Prof. Nandita deSouza. Prof.
Ter Haar heads the ICR's Therapy Ultrasound Team. She is a leading physicist
in the field, having researched the basic science behind the technique,
participating in early clinical trials and advancing device development. Prof.
deSouza is the new initiative's clinical director. She is the lead academic
radiologist at the ICR and The Royal Marsden, with an international reputation
in MRI, and has run pilot clinical trials of MR-guided thermal therapies.

About the Institute of Cancer Research (ICR)

The Institute of Cancer Research, London, is one of the world's most
influential cancer research institutes. Scientists and clinicians at The
Institute of Cancer Research (ICR) are working every day to make a real impact
on cancer patients' lives. Through its unique partnership with The Royal
Marsden NHS Foundation Trust and 'bench-to-bedside' approach, the ICR is able
to create and deliver results in a way that other institutions cannot.
Together the two organisations are rated in the top four cancer centres
globally. The ICR's mission is to make the discoveries that defeat cancer.

For more information, visit http://www.icr.ac.uk .

About the Royal Marsden

The Royal Marsden opened its doors in 1851 as the world's first hospital
dedicated to cancer diagnosis, treatment, research and education. Today,
together with its academic partner, The Institute of Cancer Research (ICR), it
is the largest and most comprehensive cancer centre in Europe treating over
50,000 NHS and private patients every year. It is a centre of excellence with
an international reputation for groundbreaking research and pioneering the
very latest in cancer treatments and technologies. Since 2004, the hospital's
charity, The Royal Marsden Cancer Charity, has helped raise over £100 million
to build theatres, diagnostic centres, and drug development units. Prince
William became President of The Royal Marsden in 2007, following a long royal
connection with the hospital. For more information, visit
http://www.royalmarsden.nhs.uk .

About the Focused Ultrasound Foundation

The Focused Ultrasound Foundation was created to improve the lives of millions
of people worldwide by accelerating the development and adoption of focused
ultrasound therapies. The Foundation works to clear the path to global
adoption by coordinating and funding research and educational activities,
creating partnerships and fostering collaboration among stakeholders, and
building awareness of the technology among patients and professionals. The
Foundation is dedicated to ensuring that focused ultrasound finds its place as
a mainstream therapy for a range of neurological disorders, including
Parkinson's disease, epilepsy and stroke as well as uterine fibroids, cancer
and other life-threatening conditions within years, not decades. Since its
establishment in 2006, the Foundation has become the largest non-governmental
source of funding for focused ultrasound research. More information about the
Charlottesville, Virginia based Foundation can be found at
http://www.fusfoundation.org .

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being
company, focused on improving people's lives through meaningful innovation in
the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the
Netherlands, Philips posted 2012 sales of EUR 24.8 billion and employs
approximately 115,000 employees with sales and services in more than 100
countries. The company is a leader in cardiac care, acute care and home
healthcare, energy efficient lighting solutions and new lighting applications,
as well as male shaving and grooming and oral healthcare. News from Philips is
located at http://www.philips.com/newscenter .

More information about Philips' activities in MR-therapy and the Sonalleve
MR-HIFU system can be found at: http://www.philips.com/sonalleve .

Contact: For further information, please contact: Rachel Bloom-Baglin, Philips
Healthcare, Tel: +1-978-7609007, E-mail: rachel.bloom-baglin@philips.com;
Steve Klink Philips Corporate Communications, Tel.: +31-6-10888824 E-mail:
steve.klink@philips.com; Dr. Claire Bithell The Institute of Cancer Research,
Tel: +44(0)207-153-5359 Email: Claire.Bithell@icr.ac.uk; Susan Klees Focused
Ultrasound Foundation, Tel: +1-434-326-9833 Email: sklees@fusfoundation.org